These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26259268)

  • 41. Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice.
    Shi J; Wen Z; Guo J; Zhang Y; Deng G; Shu Y; Wang D; Jiang Y; Kawaoka Y; Bu Z; Chen H
    Antiviral Res; 2012 Mar; 93(3):346-53. PubMed ID: 22281419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The temperature sensitivity of epidemic influenza A viruses as a marker of immunogenicity of reassortant vaccinal strains].
    Kiseleva IV; Grigor'eva EP; Naĭkhin AN; Ivanova VV; Larionova NV; Donina SA; Litvinova OM; Aleksandrova GI; Rudenko LG
    Vopr Virusol; 2003; 48(4):26-9. PubMed ID: 12945203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cold-adapted strain of A/Leningrad/134/47/57 (H2N2)--a special attenuation donor of live influenza vaccine for children and the isolation of its recombinants].
    Garmashova LM; Polezhaev FI; Aleksandrova GI
    Vopr Virusol; 1984; 29(1):28-31. PubMed ID: 6710978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy.
    Keitel WA
    Semin Pediatr Infect Dis; 2002 Apr; 13(2):112-9. PubMed ID: 12122949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparative evaluation of the reactogenicity and immunogenicity of inactivated influenza vaccines in the elderly].
    Burtseva EI; Slepushkin AN; Vlasova LN; Oskerko TA; Fedorova GI; Stepnova AI; Beregovskiĭ NA
    Zh Mikrobiol Epidemiol Immunobiol; 2000; (5):40-5. PubMed ID: 11220963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity].
    Slepushkin AN; Rudenko LG; Kendal AP; Monto AS; Beliaev AL; Burtseva EI; Grigor'eva EP; Obrosova-Serova NP; Ivanova VT; Bragina VE
    Vopr Virusol; 1994; 39(3):129-31. PubMed ID: 8091754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets.
    Yang P; Duan Y; Wang C; Xing L; Gao X; Tang C; Luo D; Zhao Z; Jia W; Peng D; Liu X; Wang X
    Vaccine; 2011 Jan; 29(4):698-705. PubMed ID: 21111782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Production of early cytokines after infection with A/Leningrad/134/57 (H2N2) wide-type virus and cold-adapted attenuated vaccine viruses].
    Rekstin AR; Lu K; Kats D; Rudenko LG
    Vopr Virusol; 2006; 51(2):27-30. PubMed ID: 16756175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
    Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
    Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.
    King JP; McLean HQ; Meece JK; Levine MZ; Spencer SM; Flannery B; Belongia EA
    Vaccine; 2018 Feb; 36(9):1214-1219. PubMed ID: 29395525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of disease.
    Rocchi G; Ragona G; Piga C; Pelosio A; Volpi A; Vella S; Legniti N; de Felici A
    J Hyg (Lond); 1979 Dec; 83(3):383-90. PubMed ID: 512351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model.
    Voeten JT; Kiseleva IV; Glansbeek HL; Basten SM; Drieszen-van der Cruijsen SK; Rudenko LG; van den Bosch H; Heldens JG
    Arch Virol; 2010 Sep; 155(9):1391-9. PubMed ID: 20532926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16.
    Nohynek H; Baum U; Syrjänen R; Ikonen N; Sundman J; Jokinen J
    Euro Surveill; 2016 Sep; 21(38):. PubMed ID: 27684447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.
    Beyer WE; Palache AM; de Jong JC; Osterhaus AD
    Vaccine; 2002 Jan; 20(9-10):1340-53. PubMed ID: 11818152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing protection against influenza in children eligible for the vaccine for children program.
    Hull HF; O'Connor H
    Pediatr Infect Dis J; 2010 Oct; 29(10):910-4. PubMed ID: 20431426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
    Smolonogina TA; Desheva IuA; Rekstin AR; Mironov AN; Rudenko LG
    Vopr Virusol; 2013; 58(6):31-5. PubMed ID: 24772644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.